Is it time to introduce anti-inflammatory drugs into secondary cardiovascular prevention: evidence from clinical trials?

Abstract

A relationship between inflammatory activity, on the one hand, and haemostasias, cardiovascular risk factors and multiple phases of atherothrombotic diseases, on the other hand, has been documented for decades, but only recently have four large trials tested whether anti-inflammatory drugs could prevent major cardiovascular events (MACE) in > 25,000 patients followed on average for 1.9-3.7 years. In patients with recent myocardial infarction (MI) and serum C-reactive protein (CRP) ≥ 2 mg/L, the CANTOS trial showed that subcutaneous three-monthly 300 mg canakinumab [a high-cost, monoclonal antibody to interleukin (IL)-1β] reduced MACE versus placebo, but it increased fatal infections. In patients with recent MI (COLCOT trial) and in patients with chronic coronary syndromes (LoDoCo2 trial), oral 0.5 mg daily colchicine [a low-cost inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family pyrin domain containing protein 3 (NLRP3) inflammasome] reduced MACE compared to placebo, with a small but significant increase in pneumonia (0.9% vs. 0.4% in COLCOT; not confirmed in LoDoCo2). In coronary artery disease patients with type 2 diabetes or metabolic syndrome, the CIRT trial found that oral 15-20 mg weekly methotrexate (an anti-rheumatic drug with multiple effects including inhibition of nuclear factor kB activity) compared to placebo did not reduce MACE, nor circulating IL-6 or CRP, while increasing the risk of non-basal cell skin cancer. Thus, three out of four large trials have now proven that drugs inhibiting the IL-1/IL-6 inflammatory axis can prevent MACE in patients with coronary artery disease. Colchicine, given its overall profile, is likely to become an integral part of secondary cardiovascular-disease prevention strategies.

Keywords

Inflammation / atherosclerosis / thrombosis / cardiovascular events / colchicine / canakinumab / methotrexate

References

[1] Kroop IG.Level of C-reactive protein as a measure of acute myocardial infarction..Proc Soc Exp Biol Med1954;86:95-7

[2] Pepys MB.Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein..Adv Immunol1983;34:141-212

[3] Andreotti F,Hackett DR.Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction..J Am Coll Cardiol1990;16:1553-60

[4] Meade TW,Brozovic M.Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study..Lancet1986;2:533-7

[5] Kannel WB.Fibrinogen and risk of cardiovascular disease: the framingham study..JAMA1987;258:1183

[6] Yarnell JW,Sweetnam PM.Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies..Circulation1991;83:836-44

[7] Liuzzo G,Gallimore JR.The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina..N Engl J Med1994;331:417-24

[8] Ross R.Atherosclerosis-an inflammatory disease..N Engl J Med1999;340:115-26

[9] Bermudez EA,Buring J,Ridker PM.Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women..Arterioscler Thromb Vasc Biol2002;22:1668-73

[10] Kohchi K,Hiroki T.Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy..Circulation1985;71:709-16

[11] Crea F.The unstable plaque: a broken balance..Eur Heart J2009;30:1821-3

[12] Hansson GK.Inflammation, atherosclerosis, and coronary artery disease..N Engl J Med2005;352:1685-95

[13] Libby P,Hansson GK.Inflammation in atherosclerosis: from pathophysiology to practice..J Am Coll Cardiol2009;54:2129-38 PMCID:PMC2834169

[14] Morton AC,Greenwood JP.The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study..Eur Heart J2015;36:377-84 PMCID:PMC4320321

[15] Ridker PM,Thuren T.Antiinflammatory therapy with canakinumab for atherosclerotic disease..N Engl J Med2017;377:1119-31

[16] Ridker PM,Pradhan A.Low-dose methotrexate for the prevention of atherosclerotic events..N Engl J Med2019;380:752-62 PMCID:PMC6587584

[17] Tardif JC,Waters DD.Efficacy and safety of low-dose colchicine after myocardial infarction..N Engl J Med2019;381:2497-505

[18] Nidorf SM,Mosterd A.Colchicine in Patients with Chronic Coronary Disease..N Engl J Med2020;383:1838-47

[19] Buckley LF.Interleukin-1 blockade in cardiovascular diseases: a clinical update..Eur Heart J2018;39:2063-9

[20] Mailer RK,Liu S,Tegner J.IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3..Sci Rep2015;5:14674 PMCID:PMC4593960

[21] Dalbeth N,Wolfe HR.Mechanism of action of colchicine in the treatment of gout..Clin Ther2014;36:1465-79

[22] El Hasbani G,Uthman I.Colchicine: An ancient drug with multiple benefits..Curr Pharm Des2020;

[23] Yang M,Liu Q.Colchicine alleviates cholesterol crystal-induced endothelial cell pyroptosis through activating AMPK/SIRT1 pathway..Oxid Med Cell Longev2020;2020:9173530 PMCID:PMC7378601

[24] Cirillo P,Pellegrino G.Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel..J Thromb Thrombolysis2020;50:468-72 PMCID:PMC7183388

[25] Cimmino G,Morello A.Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells..Vascul Pharmacol2020;106822

[26] Pratt J,Henneguelle E,Laduron PM.Neuroprotective effects of colchicine in the gerbil model of cerebral ischaemia..Neurosci Lett1994;169:114-8

[27] Bedoui Y,Sélambarom J.Methotrexate an old drug with new tricks..Int J Mol Sci2019;20:5023 PMCID:PMC6834162

[28] Ziff OJ,Howard JP.Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment..BMC Med2020;18:103 PMCID:PMC7199339

[29] Bangalore S,Radford M.Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials..Am J Med2014;127:939-53

[30] ClinicalTrails.Gov. Available from: https://www.clinicaltrials.gov/ct2/results?term=coronary+disease&cond=Inflammation&age_v=&gndr=&type=Intr&rslt=&Search=Apply [Last accessed on 15 Nov 2020]

[31] CONVINCE Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT02898610 [Last accessed on 15 Nov 2020]

[32] Chinese study. Available from: https://clinicaltrials.gov/ct2/show/NCT02035891 [Last accessed on 15 Nov 2020]

[33] COLCOVID Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT04328480 [Last accessed on 15 Nov 2020]

[34] COLCORONA Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT04322682 [Last accessed on 15 Nov 2020]

[35] Imazio M,Cemin R.A randomized trial of colchicine for acute pericarditis..N Engl J Med2013;369:1522-8